Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat
Sign Up
Cited by 3,822

The DOI matches its Crossref record; 29 of the 29 references it cites were found in a registry or an index.

2012 focused update of the ESC Guidelines for the management of atrial fibrillation

Open access
Authors/Task Force Members, Camm, A. John, Lip, Gregory Y.H., De Caterina, Raffaele, Savelieva, Irene, Atar, Dan, Hohnloser, Stefan H., Hindricks, Gerhard, Kirchhof, Paulus, ESC Committee for Practice Guidelines (CPG), Bax, Jeroen J., Baumgartner, Helmut, Ceconi, Claudio, Dean, Veronica, Deaton, Christi, Fagard, Robert, Funck-Brentano, Christian, Hasdai, David, Hoes, Arno, Kirchhof, Paulus, Knuuti, Juhani, Kolh, Philippe, McDonagh, Theresa, Moulin, Cyril, Popescu, Bogdan A., Reiner, Željko, Sechtem, Udo, Sirnes, Per Anton, Tendera, Michal, Torbicki, Adam, Vahanian, Alec, Windecker, Stephan, Document Reviewers, Vardas, Panos, Al-Attar, Nawwar, Alfieri, Ottavio, Angelini, Annalisa, Blömstrom-Lundqvist, Carina, Colonna, Paolo, De Sutter, Johan, Ernst, Sabine, Goette, Andreas, Gorenek, Bulent, Hatala, Robert, Heidbüchel, Hein, Heldal, Magnus, Kristensen, Steen Dalby, Kolh, Philippe, Le Heuzey, Jean-Yves, Mavrakis, Hercules, Mont, Lluís, Filardi, Pasquale Perrone, Ponikowski, Piotr, Prendergast, Bernard, Rutten, Frans H., Schotten, Ulrich, Van Gelder, Isabelle C., Verheugt, Freek W.A.·2012·EP Europace
DOI 10.1093/europace/eus305
Open this paper in CoChat — free account

Abstract

† Representing the European Association for Cardio-Thoracic Surgery (EACTS).Other ESC entities having participated in the development of this document:.Associations: European Association of Echocardiography (EAE), European Association for Cardiovascular Prevention and Rehabilitation (EAPCR), Heart Failure Association (HFA).Councils: Council for Cardiology Practice, Council on Primary Cardiovascular Care.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1093/europace/eus305

Cites

29 of 29 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 29 references

Research works printed but not linked: 164

  1. Camm, 2010, Guidelines for the management of atrial fibrillation: the Task Force for the Management of Atrial Fibrillation of the European Society of Cardiology (ESC), Europace, 12, 1360, 10.1093/europace/euq350 · DOI · Paper page
  2. Connolly, 2011, Dronedarone in high-risk permanent atrial fibrillation, N Engl J Med, 365, 2268, 10.1056/NEJMoa1109867 · DOI · Paper page
  3. Wann, 2011, ACCF/AHA Task Force Members. 2011 ACCF/AHA/HRS focused update on the management of patients with atrial fibrillation (Updating the 2006 Guideline): a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines, Circulation, 123, 104, 10.1161/CIR.0b013e3181fa3cf4 · DOI · Paper page
  4. Wann, 2011, 2011 ACCF/AHA/HRS focused update on the management of patients with atrial fibrillation (update on dabigatran). A report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines, Circulation, 123, 1144, 10.1161/CIR.0b013e31820f14c0 · DOI · Paper page
  5. Skanes, 2012, Focused 2012 Update of the Canadian Cardiovascular Society Atrial fibrillation Guidelines: recommendations for stroke prevention and rate/rhythm control, Can J Cardiol, 28, 125
  6. Lip, 2012, Atrial fibrillation, Lancet, 379, 648, 10.1016/S0140-6736(11)61514-6 · DOI · Paper page
  7. Kirchhof, 2012, Comprehensive risk reduction in patients with atrial fibrillation: Emerging diagnostic and therapeutic options. Executive summary of the report from the 3rd AFNET/EHRA consensus conference, Europace, 14, 8, 10.1093/europace/eur241 · DOI · Paper page
  8. Fitzmaurice, 2007, Screening vs. routine practice in detection of atrial fibrillation in patients aged 65 or over: cluster randomised controlled trial, Br Med J, 335, 383, 10.1136/bmj.39280.660567.55 · DOI · Paper page
  9. Lip, 2012, What is the most effective and safest delivery of thromboprophylaxis in atrial fibrillation?, J R Coll Physicians Edinb, 42, 35, 10.4997/JRCPE.2012.S04 · DOI
  10. Lip, 2011, Stroke in atrial fibrillation: epidemiology and thromboprophylaxis, J Thromb Haemost, 9, 344, 10.1111/j.1538-7836.2011.04302.x · DOI
  11. Wilke, 2012, Oral anticoagulation use by patients with atrial fibrillation in Germany. Adherence to guidelines, causes of anticoagulation under-use and its clinical outcomes, based on claims-data of 183,448 patients, Thromb Haemost, 107, 1053, 10.1160/TH11-11-0768 · DOI
  12. K Kirchhof, 2011, Impact of the type of centre on management of AF patients: surprising evidence for differences in antithrombotic therapy decisions, Thromb Haemost, 105, 1010, 10.1160/TH11-02-0070 · DOI
  13. Lip, 2011, The role of aspirin for stroke prevention in atrial fibrillation, Nat Rev Cardiol, 8, 602, 10.1038/nrcardio.2011.112 · DOI
  14. Olesen, 2011, Risks of thromboembolism and bleeding with thromboprophylaxis in patients with atrial fibrillation: a net clinical benefit analysis using a ‘real world’ nationwide cohort study, Thromb Haemost, 106, 739, 10.1160/TH11-05-0364 · DOI · Paper page
  15. Ogilvie, 2011, Ischaemic stroke and bleeding rates in 'real-world' atrial fibrillation patients, Thromb Haemost, 106, 34, 10.1160/TH10-10-0674 · DOI
  16. Rash, 2007, A randomised controlled trial of warfarin vs. aspirin for stroke prevention in octogenarians with atrial fibrillation (WASPO), Age Ageing, 36, 151, 10.1093/ageing/afl129 · DOI · Paper page
  17. Seshasai, 2012, Effect of aspirin on vascular and nonvascular outcomes: meta-analysis of randomized controlled trials, Arch Intern Med, 172, 209, 10.1001/archinternmed.2011.628 · DOI · Paper page
  18. De Caterina, 2012, New oral anticoagulants in atrial fibrillation and acute coronary syndromes: ESC Working Group on Thrombosis—Task Force on Anticoagulants in Heart Disease position paper, J Am Coll Cardiol, 59, 1413, 10.1016/j.jacc.2012.02.008 · DOI · Paper page
  19. Gage, 2001, Validation of clinical classification schemes for predicting stroke: results from the National Registry of Atrial Fibrillation, JAMA, 285, 2864, 10.1001/jama.285.22.2864 · DOI · Paper page
  20. Karthikeyan, 2010, The CHADS2 score for stroke risk stratification in atrial fibrillation—friend or foe?, Thromb Haemost, 104, 45, 10.1160/TH09-11-0757 · DOI
  21. Keogh, 2011, Validation of the CHADS2 clinical prediction rule to predict ischaemic stroke. A systematic review and meta-analysis, Thromb Haemost, 106, 528, 10.1160/TH11-02-0061 · DOI
  22. Lin, 2011, Risk factors and incidence of ischemic stroke in Taiwanese with nonvalvular atrial fibrillation—a nationwide database analysis, Atherosclerosis, 217, 292, 10.1016/j.atherosclerosis.2011.03.033 · DOI
  23. Olesen, 2012, Risk factors for stroke and thromboembolism in relation to age among patients with atrial fibrillation: the Loire Valley Atrial Fibrillation Project, Chest, 141, 147, 10.1378/chest.11-0862 · DOI
  24. Olesen, 2012, Vascular disease and stroke risk in atrial fibrillation: a nationwide cohort study, Am J Med, 125, 10.1016/j.amjmed.2011.11.024 · DOI
  25. van Walraven, 2009, Effect of age on stroke prevention therapy in patients with atrial fibrillation, Stroke, 40, 1410, 10.1161/STROKEAHA.108.526988 · DOI · Paper page
  26. Olesen, 2011, Validation of risk stratification schemes for predicting stroke and thromboembolism in patients with atrial fibrillation: nationwide cohort study, Br Med J, 342, 10.1136/bmj.d124 · DOI · Paper page
  27. Potpara, 2012, Reliable identification of ‘truly low’ thromboembolic risk in patients initially diagnosed with ‘lone’ atrial fibrillation: the Belgrade Atrial Fibrillation Study, Circ Arrhythm Electrophysiol, 5, 319, 10.1161/CIRCEP.111.966713 · DOI
  28. Olesen, 2012, The value of the CHA2DS2-VASc score for refining stroke risk stratification in patients with atrial fibrillation with a CHADS2 score 0–1: a nationwide cohort study, Thromb Haemost, 107, 1172, 10.1160/TH12-03-0175 · DOI · Paper page
  29. Lip, 2010, Refining clinical risk stratification for predicting stroke and thromboembolism in atrial fibrillation using a novel risk factor-based approach: the Euro Heart Survey on Atrial Fibrillation, Chest, 137, 263, 10.1378/chest.09-1584 · DOI · Paper page
  30. Stroke Risk in Atrial Fibrillation Working Group, 2007, Independent predictors of stroke in patients with atrial fibrillation: a systematic review, Neurology, 69, 546, 10.1212/01.wnl.0000267275.68538.8d · DOI · Paper page
  31. AF-Investigators, 1998, Echocardiographic predictors of stroke in patients with atrial fibrillation: a prospective study of 1066 patients from 3 clinical trials, Arch Intern Med, 158, 1316, 10.1001/archinte.158.12.1316 · DOI · Paper page
  32. Banerjee, 2012, Ejection fraction and outcomes in patients with atrial fibrillation and heart failure: the Loire Valley Atrial Fibrillation Project, Eur J Heart Fail, 14, 295, 10.1093/eurjhf/hfs005 · DOI
  33. Friberg, 2012, Assessment of female sex as a risk factor in atrial fibrillation in Sweden: nationwide retrospective cohort study, BMJ, 344, 10.1136/bmj.e3522 · DOI · Paper page
  34. Avgil Tsadok, 2012, Sex differences in stroke risk among older patients with recently diagnosed atrial fibrillation, JAMA, 307, 1952, 10.1001/jama.2012.3490 · DOI · Paper page
  35. Van Staa, 2011, A comparison of risk stratification schemes for stroke in 79,884 atrial fibrillation patients in general practice, J Thromb Haemost, 9, 39, 10.1111/j.1538-7836.2010.04085.x · DOI · Paper page
  36. Abu-Assi, Comparison of the reliability and validity of four contemporary risk stratification schemes to predict thromboembolism in non-anticoagulated patients with atrial fibrillation, Int J Cardiol.
  37. Boriani, 2011, Improving stroke risk stratification using the CHADS2 and CHA2DS2-VASc risk scores in patients with paroxysmal atrial fibrillation by continuous arrhythmia burden monitoring, Stroke, 42, 1768, 10.1161/STROKEAHA.110.609297 · DOI · Paper page
  38. Chao, 2011, CHADS(2) and CHA(2)DS(2)-VASc scores in the prediction of clinical outcomes in patients with atrial fibrillation after catheter ablation, J Am Coll Cardiol, 58, 2380, 10.1016/j.jacc.2011.08.045 · DOI
  39. Connolly, 2011, Net clinical benefit of adding clopidogrel to aspirin therapy in patients with atrial fibrillation for whom vitamin K antagonists are unsuitable, Ann Intern Med, 155, 579, 10.7326/0003-4819-155-9-201111010-00004 · DOI
  40. Lip, 2011, Bleeding risk assessment, management in atrial fibrillation patients. Executive Summary of a Position Document from the European Heart Rhythm Association [EHRA], endorsed by the European Society of Cardiology [ESC] Working Group on Thrombosis, Europace, 13, 723, 10.1093/europace/eur126 · DOI · Paper page
  41. Gage, 2006, Clinical classification schemes for predicting hemorrhage: results from the National Registry of Atrial Fibrillation (NRAF), Am Heart J, 151, 713, 10.1016/j.ahj.2005.04.017 · DOI · Paper page
  42. Pisters, 2010, A novel user-friendly score (HAS-BLED) to assess 1-year risk of major bleeding in patients with atrial fibrillation: the Euro Heart Survey, Chest, 138, 1093, 10.1378/chest.10-0134 · DOI · Paper page
  43. Fang, 2011, A new risk scheme to predict warfarin-associated hemorrhage: The ATRIA (Anticoagulation and Risk Factors in Atrial Fibrillation) Study, J Am Coll Cardiol, 58, 395, 10.1016/j.jacc.2011.03.031 · DOI · Paper page
  44. Cairns, 2011, Canadian Cardiovascular Society atrial fibrillation Guidelines 2010: prevention of stroke and systemic thromboembolism in atrial fibrillation and flutter, Can J Cardiol, 27, 74
  45. Roldan, Predictive value of the HAS-BLED and ATRIA bleeding scores for the risk of serious bleeding in a 'real world' anticoagulated atrial fibrillation population, Chest., 10.1378/chest.12-0608 · DOI · Paper page
  46. Apostolakis, 2012, Performance of the HEMORR2HAGES, ATRIA and HAS-BLED bleeding risk prediction scores in anticoagulated patients with atrial fibrillation: The AMADEUS study, J Am Coll Cardiol, 60, 861, 10.1016/j.jacc.2012.06.019 · DOI · Paper page
  47. Lip, 2011, Comparative validation of a novel risk score for predicting bleeding risk in anticoagulated patients with atrial fibrillation: the HAS-BLED (Hypertension, Abnormal renal/liver function, Stroke, Bleeding history or predisposition, Labile INR, Elderly, Drugs/alcohol concomitantly) score, J Am Coll Cardiol, 57, 173, 10.1016/j.jacc.2010.09.024 · DOI · Paper page
  48. Olesen, 2011, Bleeding risk in ‘real world’ patients with atrial fibrillation: comparison of two established bleeding prediction schemes in a nationwide cohort, J Thromb Haemost, 9, 1460, 10.1111/j.1538-7836.2011.04378.x · DOI · Paper page
  49. Gallego, 2012, Relation of the HAS-BLED bleeding risk score to major bleeding, cardiovascular events and mortality in anticoagulated patients with atrial fibrillation, Circ Arrhythm Electrophysiol, 5, 312, 10.1161/CIRCEP.111.967000 · DOI
  50. Lane, 2012, Use of the CHA2DS2-VASc and HAS-BLED scores to aid decision making for thromboprophylaxis in non-valvular atrial fibrillation, Circulation, 126, 860, 10.1161/CIRCULATIONAHA.111.060061 · DOI · Paper page
  51. Connolly, 2008, Benefit of oral anticoagulant over antiplatelet therapy in atrial fibrillation depends on the quality of international normalized ratio control achieved by centers and countries as measured by time in therapeutic range, Circulation, 118, 2029, 10.1161/CIRCULATIONAHA.107.750000 · DOI · Paper page
  52. Gallagher, 2011, Risks of stroke and mortality associated with suboptimal anticoagulation in atrial fibrillation patients, Thromb Haemost, 106, 968, 10.1160/TH11-05-0353 · DOI · Paper page
  53. Wallentin, 2010, Efficacy and safety of dabigatran compared with warfarin at different levels of international normalised ratio control for stroke prevention in atrial fibrillation: an analysis of the RE-LY trial, Lancet, 376, 975, 10.1016/S0140-6736(10)61194-4 · DOI · Paper page
  54. Morgan, 2009, Warfarin treatment in patients with atrial fibrillation: observing outcomes associated with varying levels of INR control, Thromb Res, 124, 37, 10.1016/j.thromres.2008.09.016 · DOI · Paper page
  55. Ahrens, 2010, New oral anticoagulant drugs in cardiovascular disease, Thromb Haemost, 104, 49, 10.1160/TH09-05-0327 · DOI · Paper page
  56. Ruff, 2010, Evaluation of the novel factor Xa inhibitor edoxaban compared with warfarin in patients with atrial fibrillation: design and rationale for the Effective aNticoaGulation with factor xA next GEneration in Atrial Fibrillation-Thrombolysis In Myocardial Infarction study 48 (ENGAGE AF-TIMI 48), Am Heart J, 160, 635, 10.1016/j.ahj.2010.06.042 · DOI · Paper page
  57. Hohnloser, 2012, Myocardial ischemic events in patients with atrial fibrillation treated with dabigatran or warfarin in the RE-LY (Randomized Evaluation of Long-Term Anticoagulation Therapy) trial, Circulation, 125, 669, 10.1161/CIRCULATIONAHA.111.055970 · DOI · Paper page
  58. Oldgren, 2011, Risks for stroke, bleeding, and death in patients with atrial fibrillation receiving dabigatran or warfarin in relation to the CHADS2 score: a subgroup analysis of the RE-LY trial, Ann Intern Med, 155, 660, 10.7326/0003-4819-155-10-201111150-00004 · DOI · Paper page
  59. Ezekowitz, 2010, Dabigatran and warfarin in vitamin K antagonist-naive and -experienced cohorts with atrial fibrillation, Circulation, 122, 2246, 10.1161/CIRCULATIONAHA.110.973735 · DOI · Paper page
  60. Uchino, 2012, Dabigatran association with higher risk of acute coronary events: meta-analysis of noninferiority randomized controlled trials, Arch Intern Med, 172, 397, 10.1001/archinternmed.2011.1666 · DOI · Paper page
  61. Lip, 2010, Does warfarin for stroke thromboprophylaxis protect against MI in atrial fibrillation patients?, Am J Med, 123, 785, 10.1016/j.amjmed.2010.01.031 · DOI
  62. Lip, 2012, Indirect comparisons of new oral anticoagulant drugs for efficacy and safety when used for stroke prevention in atrial fibrillation, J Am Coll Cardiol, 60, 738, 10.1016/j.jacc.2012.03.019 · DOI · Paper page
  63. Freeman, 2011, Cost-effectiveness of dabigatran compared with warfarin for stroke prevention in atrial fibrillation, Ann Intern Med, 154, 1, 10.7326/0003-4819-154-1-201101040-00289 · DOI · Paper page
  64. Sorensen, 2011, Cost-effectiveness of dabigatran etexilate for the prevention of stroke and systemic embolism in atrial fibrillation: a Canadian payer perspective, Thromb Haemost, 105, 908, 10.1160/TH11-02-0089 · DOI · Paper page
  65. Pink, 2011, Dabigatran etexilate vs. warfarin in management of non-valvular atrial fibrillation in UK context: quantitative benefit-harm and economic analyses, BMJ, 343, 10.1136/bmj.d6333 · DOI · Paper page
  66. Shah, 2011, Cost-effectiveness of dabigatran for stroke prophylaxis in atrial fibrillation, Circulation, 123, 2562, 10.1161/CIRCULATIONAHA.110.985655 · DOI · Paper page
  67. Banerjee, 2012, Net clinical benefit of new oral anticoagulants (dabigatran, rivaroxaban, apixaban) vs. no treatment in a ‘real world’ atrial fibrillation population: a modelling analysis based on a nationwide cohort study, Thromb Haemost, 107, 584, 10.1160/TH11-11-0784 · DOI · Paper page
  68. Douxfils, 2012, Impact of dabigatran on a large panel of routine or specific coagulation assays. Laboratory recommendations for monitoring of dabigatran etexilate, Thromb Haemost, 107, 985, 10.1160/TH11-11-0804 · DOI · Paper page
  69. van Ryn, 2010, Dabigatran etexilate—a novel, reversible, oral direct thrombin inhibitor: interpretation of coagulation assays and reversal of anticoagulant activity, Thromb Haemost, 103, 1116, 10.1160/TH09-11-0758 · DOI · Paper page
  70. Huisman, 2012, Dabigatran etexilate for stroke prevention in patients with atrial fibrillation: resolving uncertainties in routine practice, Thromb Haemost, 107, 838, 10.1160/TH11-10-0718 · DOI · Paper page
  71. Tripodi, 2011, Measuring the anticoagulant effect of direct factor Xa inhibitors. Is the anti-Xa assay preferable to the prothrombin time test?, Thromb Haemost, 105, 735, 10.1160/TH10-11-0718 · doi:10.1160/th10-11-0718
  72. Barrett, 2010, Clinical laboratory measurement of direct factor Xa inhibitors: anti-Xa assay is preferable to prothrombin time assay, Thromb Haemost, 104, 1263, 10.1160/TH10-05-0328 · DOI · Paper page
  73. Pengo, 2011, Questions and answers on the use of dabigatran and perspectives on the use of other new oral anticoagulants in patients with atrial fibrillation. A consensus document of the Italian Federation of Thrombosis Centers (FCSA), Thromb Haemost, 106, 868, 10.1160/TH11-05-0358 · DOI · Paper page
  74. Eerenberg, 2011, Reversal of rivaroxaban and dabigatran by prothrombin complex concentrate: a randomized, placebo-controlled, crossover study in healthy subjects, Circulation, 124, 1573, 10.1161/CIRCULATIONAHA.111.029017 · DOI · Paper page
  75. Marlu, 2012, Effect of non-specific reversal agents on anticoagulant activity of dabigatran , rivaroxaban. A randomised crossover ex vivo study in healthy volunteers, Thromb Haemost, 108, 217, 10.1160/TH12-03-0179 · DOI · Paper page
  76. Sié, 2011, Surgery and invasive procedures in patients on long-term treatment with direct oral anticoagulants: thrombin or factor-Xa inhibitors. Recommendations of the Working Group on Perioperative Haemostasis and the French Study Group on Thrombosis and Haemostasis, Arch Cardiovasc Dis, 104, 669, 10.1016/j.acvd.2011.09.001 · DOI · Paper page
  77. Omran, 2012, The HAS-BLED score predicts bleedings during bridging of chronic oral anticoagulation. Results from the national multicentre BNK Online bRiDging REgistRy (BORDER), Thromb Haemost, 108, 65, 10.1160/TH11-12-0827 · DOI · Paper page
  78. Nagarakanti, 2011, Dabigatran vs. warfarin in patients with atrial fibrillation: an analysis of patients undergoing cardioversion, Circulation, 123, 131, 10.1161/CIRCULATIONAHA.110.977546 · DOI · Paper page
  79. Winkle, 2011, The use of dabigatran immediately after atrial fibrillation ablation, J Cardiovasc Electrophysiol, 23, 264, 10.1111/j.1540-8167.2011.02175.x · DOI
  80. Lakkireddy, 2012, Feasibility and safety of dabigatran vs. warfarin for periprocedural anticoagulation in patients undergoing radiofrequency ablation for atrial Fibrillation results from a multicenter prospective registry, J Am Coll Cardiol, 59, 1168, 10.1016/j.jacc.2011.12.014 · DOI · Paper page
  81. Ruiz-Nodar, 2012, Should we recommend oral anticoagulation therapy in patients with atrial fibrillation undergoing coronary artery stenting with a high HAS-BLED bleeding risk score?, Circ Cardiovasc Interv, 5, 459, 10.1161/CIRCINTERVENTIONS.112.968792 · DOI
  82. Lip, 2010, Antithrombotic management of atrial fibrillation patients presenting with acute coronary syndrome and/or undergoing coronary stenting, Eur Heart J, 31, 1311, 10.1093/eurheartj/ehq117 · DOI
  83. Huber, 2011, Antithrombotic therapy in patients with atrial fibrillation undergoing coronary stenting: similarities and dissimilarities between North America and Europe, Thromb Haemost, 106, 569, 10.1160/TH11-08-0602 · DOI
  84. Faxon, 2011, Consensus document: antithrombotic therapy in patients with atrial fibrillation undergoing coronary stenting. A North-American perspective, Thromb Haemost, 106, 572
  85. Mega, 2012, Rivaroxaban in patients with a recent acute coronary syndrome, N Engl J Med, 366, 9, 10.1056/NEJMoa1112277 · DOI · Paper page
  86. Alexander, 2011, Apixaban with antiplatelet therapy after acute coronary syndrome, N Engl J Med, 365, 699, 10.1056/NEJMoa1105819 · DOI · Paper page
  87. Matute, 2012, Safety and outcomes following thrombolytic treatment in stroke patients who had received prior treatment with anticoagulants, Cerebrovasc Dis, 33, 231, 10.1159/000334662 · DOI
  88. Potpara, 2012, Reliable identification of 'truly low' thromboembolic risk in patients initially diagnosed with 'lone' atrial fibrillation: The Belgrade Atrial Fibrillation Study, Circ Arrhythm Electrophysiol, 5, 319, 10.1161/CIRCEP.111.966713 · DOI
  89. Singer, 2009, The net clinical benefit of warfarin anticoagulation in atrial fibrillation, Ann Intern Med, 151, 297, 10.7326/0003-4819-151-5-200909010-00003 · DOI · Paper page
  90. De Caterina, 2010, Mortality predictors and effects of antithrombotic therapies in atrial fibrillation: insights from ACTIVE-W, Eur Heart J, 31, 2133, 10.1093/eurheartj/ehq250 · DOI
  91. Hylek, 2006, Translating the results of randomized trials into clinical practice: the challenge of warfarin candidacy among hospitalized elderly patients with atrial fibrillation, Stroke, 37, 1075, 10.1161/01.STR.0000209239.71702.ce · DOI
  92. Corley, 2004, Relationships between sinus rhythm, treatment, and survival in the Atrial Fibrillation Follow-Up Investigation of Rhythm Management (AFFIRM) Study, Circulation, 109, 1509, 10.1161/01.CIR.0000121736.16643.11 · DOI · Paper page
  93. Klein, 2001, Use of transesophageal echocardiography to guide cardioversion in patients with atrial fibrillation, N Engl J Med, 344, 1411, 10.1056/NEJM200105103441901 · DOI · Paper page
  94. Cox, 2004, Cardiac surgery for arrhythmias, J Cardiovasc Electrophysiol, 15, 250, 10.1046/j.1540-8167.2004.03656.x · DOI
  95. Bayard, 2010, PLAATO (Percutaneous Left Atrial Appendage Transcatheter Occlusion) for prevention of cardioembolic stroke in non-anticoagulation eligible atrial fibrillation patients: results from the European PLAATO study, EuroIntervention, 6, 220, 10.4244/EIJV6I2A35 · DOI · Paper page
  96. Park, 2011, Catheter Cardiovasc Interv, 77, 700
  97. Holmes, 2009, Percutaneous closure of the left atrial appendage vs. warfarin therapy for prevention of stroke in patients with atrial fibrillation: a randomised non-inferiority trial, Lancet, 374, 534, 10.1016/S0140-6736(09)61343-X · DOI · Paper page
  98. Whitlock, 2009, Left atrial appendage occlusion does not eliminate the need for warfarin, Circulation, 120, 1927, 10.1161/CIRCULATIONAHA.108.844779 · DOI
  99. Dawson, 2010, Should patients undergoing cardiac surgery with atrial fibrillation have left atrial appendage exclusion?, Interact Cardiovasc Thorac Surg, 10, 306, 10.1510/icvts.2009.227991 · DOI
  100. Reddy, 2011, Safety of percutaneous left atrial appendage closure: results from the Watchman left atrial appendage system for embolic protection in patients with AF (PROTECT AF) clinical trial and the Continued Access Registry, Circulation, 123, 417, 10.1161/CIRCULATIONAHA.110.976449 · DOI · Paper page
  101. Roy, 2004, A randomized, controlled trial of RSD1235, a novel anti-arrhythmic agent, in the treatment of recent onset atrial fibrillation, J Am Coll Cardiol, 44, 2355, 10.1016/j.jacc.2004.09.021 · doi:10.1016/j.jacc.2004.09.021
  102. Roy, 2008, Vernakalant hydrochloride for rapid conversion of atrial fibrillation: a phase 3, randomized, placebo-controlled trial, Circulation, 117, 1518, 10.1161/CIRCULATIONAHA.107.723866 · DOI · Paper page
  103. Pratt, 2010, Usefulness of vernakalant hydrochloride injection for rapid conversion of atrial fibrillation, Am J Cardiol, 106, 1277, 10.1016/j.amjcard.2010.06.054 · doi:10.1016/j.amjcard.2010.06.054
  104. Kowey, 2009, Vernakalant hydrochloride for the rapid conversion of atrial fibrillation after cardiac surgery: a randomized, double-blind, placebo-controlled trial, Circ Arrhythm Electrophysiol, 2, 652, 10.1161/CIRCEP.109.870204 · DOI · Paper page
  105. Stiell, 2010, A multicenter, open-label study of vernakalant for the conversion of atrial fibrillation to sinus rhythm, Am Heart J, 159, 1095, 10.1016/j.ahj.2010.02.035 · DOI
  106. Camm, 2011, A randomized active-controlled study comparing the efficacy and safety of vernakalant to amiodarone in recent-onset atrial fibrillation, J Am Coll Cardiol, 57, 313, 10.1016/j.jacc.2010.07.046 · DOI · Paper page
  107. Buccelletti, 2011, Efficacy and safety of vernakalant in recent-onset atrial fibrillation after the European Medicines Agency approval: systematic review and meta-analysis, J Clin Pharmacol
  108. Bash, 2012, Systematic review and meta-analysis of the efficacy of cardioversion by vernakalant and comparators in patients with atrial fibrillation, Cardiovasc Drugs Ther, 26, 167, 10.1007/s10557-012-6374-4 · DOI
  109. Torp-Pedersen, Vernakalant: conversion of atrial fibrillation in patients with ischemic heart disease, Int J Cardiol
  110. Camm, 2012, Efficacy and safety of vernakalant in patients with atrial flutter: a randomized, double-blind, placebo-controlled trial, Europace, 14, 804, 10.1093/europace/eur416 · DOI
  111. Slavik, 2001, Pharmacologic conversion of atrial fibrillation: a systematic review of available evidence. Prog Cardiovasc Dis, 44, 121
  112. Stambler, 1996, Efficacy and safety of repeated intravenous doses of ibutilide for rapid conversion of atrial flutter or fibrillation, Circulation, 94, 1613, 10.1161/01.CIR.94.7.1613 · DOI · Paper page
  113. Volgman, 1998, Conversion efficacy and safety of intravenous ibutilide compared with intravenous procainamide in patients with atrial flutter or fibrillation, J Am Coll Cardiol, 31, 1414, 10.1016/S0735-1097(98)00078-3 · DOI · Paper page
  114. Savelieva, 2011, Upstream therapies for management of atrial fibrillation: review of clinical evidence and implications for European Society of Cardiology Guidelines. Part I: primary prevention, Europace, 13, 308, 10.1093/europace/eur002 · DOI · Paper page
  115. Savelieva, 2011, Upstream therapies for management of atrial fibrillation: review of clinical evidence and implications for European Society of Cardiology Guidelines. Part II: secondary prevention, Europace, 13, 610, 10.1093/europace/eur023 · DOI
  116. Yamashita, 2011, Randomized trial of angiotensin II-receptor blocker vs. dihydropiridine calcium channel blocker in the treatment of paroxysmal atrial fibrillation with hypertension (J-RHYTHM II study), Europace, 13, 473, 10.1093/europace/euq439 · DOI
  117. Lafuente-Lafuente, 2006, Antiarrhythmic drugs for maintaining sinus rhythm after cardioversion of atrial fibrillation: a systematic review of randomized controlled trials, Arch Intern Med, 166, 719, 10.1001/archinte.166.7.719 · DOI · Paper page
  118. Piccini, 2009, Comparative efficacy of dronedarone and amiodarone for the maintenance of sinus rhythm in patients with atrial fibrillation, J Am Coll Cardiol, 54, 1089, 10.1016/j.jacc.2009.04.085 · DOI · Paper page
  119. Sullivan, Interventions for the treatment of atrial fibrillation: A systematic literature review and meta-analysis, Int J Cardiol.
  120. Kirchhof, 2012, Short-term versus long-term antiarrhythmic drug treatment after cardioversion of atrial fibrillation (Flec-SL): a prospective, randomised, open-label, blinded endpoint assessment trial, Lancet, 380, 238, 10.1016/S0140-6736(12)60570-4 · DOI · Paper page
  121. Ahmed, 2008, Continuous vs. episodic prophylactic treatment with amiodarone for the prevention of atrial fibrillation: a randomized trial, JAMA, 300, 1784, 10.1001/jama.300.15.1784 · DOI
  122. Connolly, 1999, Evidence-based analysis of amiodarone efficacy and safety, Circulation, 100, 2025, 10.1161/01.CIR.100.19.2025 · DOI · Paper page
  123. Hohnloser, 2009, Effect of dronedarone on cardiovascular events in atrial fibrillation, N Engl J Med, 360, 668, 10.1056/NEJMoa0803778 · DOI · Paper page
  124. Køber, 2008, Increased mortality after dronedarone therapy for severe heart failure, N Engl J Med, 358, 2678, 10.1056/NEJMoa0800456 · DOI · Paper page
  125. Duray, 2010, Dronedarone therapy in atrial fibrillation: a summary of recent controlled trials, J Cardiovasc Pharmacol Ther, 15, 19S, 10.1177/1074248410368530 · DOI
  126. Camm, 2012, Atrial fibrillation: the rate vs. rhythm management controversy, J R Coll Physicians Edinb, 42, 23, 10.4997/JRCPE.2012.S03 · DOI
  127. Touboul, 2003, Dronedarone for prevention of atrial fibrillation: a dose-ranging study, Eur Heart J, 24, 1481, 10.1016/S0195-668X(03)00321-X · DOI · Paper page
  128. Singh, 2007, Dronedarone for maintenance of sinus rhythm in atrial fibrillation or flutter, N Engl J Med, 357, 987, 10.1056/NEJMoa054686 · DOI · Paper page
  129. Davy, 2008, Dronedarone for the control of ventricular rate in permanent atrial fibrillation: the Efficacy and safety of dRonedArone for the cOntrol of ventricular rate during atrial fibrillation (ERATO) study, Am Heart J, 156, 10.1016/j.ahj.2008.06.010 · DOI · Paper page
  130. Le Heuzey, 2010, A short-term, randomized, double-blind, parallel-group study to evaluate the efficacy and safety of dronedarone vs. amiodarone in patients with persistent atrial fibrillation: the DIONYSOS study, J Cardiovasc Electrophysiol, 21, 597, 10.1111/j.1540-8167.2010.01764.x · DOI · Paper page
  131. Morillo, Radiofrequency Ablation vs. Antiarrhythmic Drugs as First-Line Treatment of Symptomatic Atrial Fibrillation: (RAAFT 2): A randomized trial, Heart Rhythm Society 2012 Scientific Sessions; May 11, 2012; Boston, MA. Abstract LB02-1
  132. Boersma, 2012, Atrial fibrillation catheter ablation vs. surgical ablation treatment (FAST): a 2-center randomized clinical trial, Circulation, 125, 23, 10.1161/CIRCULATIONAHA.111.074047 · DOI · Paper page
  133. Pison, 2012, Hybrid thoracoscopic surgical and transvenous catheter ablation of atrial fibrillation, J Am Coll Cardiol, 60, 54, 10.1016/j.jacc.2011.12.055 · DOI · Paper page
  134. Weerasooriya, 2011, Catheter ablation for atrial fibrillation: are results maintained at 5 years of follow-up?, J Am Coll Cardiol, 57, 160, 10.1016/j.jacc.2010.05.061 · DOI · Paper page
  135. Ouyang, 2010, Long-term results of catheter ablation in paroxysmal atrial fibrillation: lessons from a 5-year follow-up, Circulation, 122, 2368, 10.1161/CIRCULATIONAHA.110.946806 · DOI · Paper page
  136. Tzou, 2010, Long-term outcome after successful catheter ablation of atrial fibrillation, Circ Arrhythm Electrophysiol, 3, 237, 10.1161/CIRCEP.109.923771 · DOI
  137. Oral, 2002, Clinical significance of early recurrences of atrial fibrillation after pulmonary vein isolation, J Am Coll Cardiol, 40, 100, 10.1016/S0735-1097(02)01939-3 · DOI · Paper page
  138. Lellouche, 2008, Early recurrences after atrial fibrillation ablation: prognostic value and effect of early reablation, J Cardiovasc Electrophysiol, 19, 599, 10.1111/j.1540-8167.2008.01188.x · DOI
  139. Pokushalov, Does atrial fibrillation burden measured by continuous monitoring during the blanking period predict the response to ablation at 12-month follow-up?, Heart Rhythm.
  140. Medi, 2011, Pulmonary vein antral isolation for paroxysmal atrial fibrillation: results from long-term follow-up, J Cardiovasc Electrophysiol, 22, 137
  141. Lee, 2011, Low risk of major complications associated with pulmonary vein antral isolation for atrial fibrillation: results of 500 consecutive ablation procedures in patients with low prevalence of structural heart disease from a single center, J Cardiovasc Electrophysiol, 22, 163
  142. Arbelo, 2012, ESC-EURObservational research programme: the atrial fibrillation ablation pilot study, conducted by the European Heart Rhythm Association, Europace, 14, 1094, 10.1093/europace/eus153 · DOI
  143. Hoyt, 2011, Complications arising from catheter ablation of atrial fibrillation: temporal trends and predictors, Heart Rhythm, 8, 1869, 10.1016/j.hrthm.2011.07.025 · DOI · Paper page
  144. Shah, 2012, Procedural complications, rehospitalizations, and repeat procedures after catheter ablation for atrial fibrillation, J Am Coll Cardiol, 59, 143, 10.1016/j.jacc.2011.08.068 · DOI · Paper page
  145. Herrera Siklódy, 2011, Incidence of asymptomatic intracranial embolic events after pulmonary vein isolation: comparison of different atrial fibrillation ablation technologies in a multicenter study, J Am Coll Cardiol, 58, 681, 10.1016/j.jacc.2011.04.010 · DOI · Paper page
  146. Di Biase, 2010, Periprocedural stroke and management of major bleeding complications in patients undergoing catheter ablation of atrial fibrillation: the impact of periprocedural therapeutic international normalized ratio, Circulation, 121, 2550, 10.1161/CIRCULATIONAHA.109.921320 · DOI · Paper page
  147. Gaita, 2011, Incidence of silent cerebral thromboembolic lesions after atrial fibrillation ablation may change according to technology used: comparison of irrigated radiofrequency, multipolar nonirrigated catheter and cryoballoon, J Cardiovasc Electrophysiol, 22, 961, 10.1111/j.1540-8167.2011.02050.x · DOI · Paper page
  148. Kirchhof, 2009, Early and comprehensive management of atrial fibrillation: proceedings from the 2nd AFNET/EHRA consensus conference on atrial fibrillation entitled ‘research perspectives in atrial fibrillation’, Europace, 11, 860, 10.1093/europace/eup124 · DOI
  149. Van Gelder, 2011, Rationale and current perspective for early rhythm control therapy in atrial fibrillation, Europace, 13, 1517, 10.1093/europace/eur192 · DOI
  150. Schmidt, 2009, Atrial fibrillation ablation in patients with therapeutic international normalized ratios, Pacing Clin Electrophysiol, 32, 995, 10.1111/j.1540-8159.2009.02429.x · DOI
  151. Page, 2011, Catheter ablation for atrial fibrillation on uninterrupted warfarin: can it be done without echo guidance?, J Cardiovasc Electrophysiol, 22, 265, 10.1111/j.1540-8167.2010.01910.x · DOI
  152. Gautam, 2011, Effect of therapeutic INR on activated clotting times, heparin dosage, and bleeding risk during ablation of atrial fibrillation, J Cardiovasc Electrophysiol, 22, 248, 10.1111/j.1540-8167.2010.01894.x · DOI
  153. Gopinath, 2011, Pulmonary vein antrum isolation for atrial fibrillation on therapeutic coumadin: special considerations, J Cardiovasc Electrophysiol, 22, 236
  154. Hakalahti, 2011, Catheter ablation of atrial fibrillation in patients with therapeutic oral anticoagulation treatment, Europace, 13, 640, 10.1093/europace/eur038 · DOI
  155. Latchamsetty, 2011, Management and outcomes of cardiac tamponade during atrial fibrillation ablation in the presence of therapeutic anticoagulation with warfarin, Heart Rhythm, 8, 805, 10.1016/j.hrthm.2011.01.020 · DOI
  156. Calkins, 2012, 2012 HRS/EHRA/ECAS Expert Consensus Statement on Catheter and Surgical Ablation of Atrial Fibrillation: recommendations for patient selection, procedural techniques, patient management and follow-up, definitions, endpoints, and research trial design, Europace, 14, 528, 10.1093/europace/eus027 · DOI · Paper page
  157. Kirchhof, 2012, Comprehensive risk reduction in patients with atrial fibrillation: emerging diagnostic and therapeutic options–a report from the 3rd Atrial Fibrillation Competence NETwork/European Heart Rhythm Association consensus conference, Europace, 14, 8, 10.1093/europace/eur241 · DOI · Paper page
  158. Van Gelder, 2011, Rationale and current perspective for early rhythm control therapy in atrial fibrillation, Europace, 13, 1517, 10.1093/europace/eur192 · DOI
  159. Pappone, 2011, Radiofrequency catheter ablation and antiarrhythmic drug therapy: a prospective, randomized, 4-year follow-up trial: the APAF study, Circ Arrhythm Electrophysiol, 4, 808, 10.1161/CIRCEP.111.966408 · DOI
  160. Tanner, 2011, Complications arising from catheter ablation of atrial fibrillation: temporal trends and predictors, Europace, 13, 646, 10.1093/europace/eur065 · DOI
  161. Wazni, 2011, Catheter ablation for atrial fibrillation, N Engl J Med, 365, 2296, 10.1056/NEJMct1109977 · DOI
  162. Wilber, 2010, Comparison of antiarrhythmic drug therapy and radiofrequency catheter ablation in patients with paroxysmal atrial fibrillation: a randomized controlled trial, JAMA, 303, 333, 10.1001/jama.2009.2029 · DOI · Paper page
  163. Haïssaguerre, 1998, Spontaneous initiation of atrial fibrillation by ectopic beats originating in the pulmonary veins, N Engl J Med, 339, 659, 10.1056/NEJM199809033391003 · DOI · Paper page
  164. Leong-Sit, 2011, Antiarrhythmics after ablation of atrial fibrillation (5A Study): six-month follow-up study, Circ Arrhythm Electrophysiol, 4, 11, 10.1161/CIRCEP.110.955393 · DOI · Paper page

Cited by

See all 3,822

Metadata

Authors
Authors/Task Force Members, Camm, A. J., Lip, G. Y. H., De Caterina, R., Savelieva, I., Atar, D., Hohnloser, S. H., Hindricks, G., Kirchhof, P., ESC Committee for Practice Guidelines (CPG), Bax, J. J., Baumgartner, H., Ceconi, C., Dean, V., Deaton, C., Fagard, R., Funck-Brentano, C., Hasdai, D., Hoes, A., Kirchhof, P., Knuuti, J., Kolh, P., McDonagh, T., Moulin, C., Popescu, B. A., Reiner, Ž., Sechtem, U., Sirnes, P. A., Tendera, M., Torbicki, A., Vahanian, A., Windecker, S., Reviewers, D., Vardas, P., Al-Attar, N., Alfieri, O., Angelini, A., Blömstrom-Lundqvist, C., Colonna, P., De Sutter, J., Ernst, S., Goette, A., Gorenek, B., Hatala, R., Heidbüchel, H., Heldal, M., Kristensen, S. D., Kolh, P., Le Heuzey, J.-Y., Mavrakis, H., Mont, L., Filardi, P. P., Ponikowski, P., Prendergast, B., Rutten, F. H., Schotten, U., Van Gelder, I. C., & Verheugt, F. W. A.
Venue
EP Europace
Publisher
Oxford University Press (OUP)
Published
2012-08-24
Volume
14
Issue
10
Pages
1385-1413
ISSN
  • 1099-5129 (ISSN-L)
  • 1532-2092
DOI
10.1093/europace/eus305
OpenAlex
W2023143117
Cited by
3,822
References
29
FWCI
363.33
Type
journal article
Language
en
Open access
bronze

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: 2012 focused update of the ESC Guidelines for the management of atrial fibrillation. https://app.cochat.ai/papers/10.1093/europace/eus305
The paper
Authors/Task Force Members, Camm, A. J., Lip, G. Y. H., De Caterina, R., Savelieva, I., Atar, D., Hohnloser, S. H., Hindricks, G., Kirchhof, P., ESC Committee for Practice Guidelines (CPG), Bax, J. J., Baumgartner, H., Ceconi, C., Dean, V., Deaton, C., Fagard, R., Funck-Brentano, C., Hasdai, D., Hoes, A., . . . Verheugt, F. W. A. (2012). 2012 focused update of the ESC Guidelines for the management of atrial fibrillation. EP Europace. https://doi.org/10.1093/europace/eus305

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.